Blogs about: Kinase Receptor
Featured Blog
Five Prime initiate Phase I trial of FGFR1:Fc fusion protein
Five Prime have initiated a Phase I trial of its FGFR1:Fc fusion protein FP-1039, in patients with advanced solid tumors.… more →
Kinase News
Five Prime initiate Phase I trial of FGFR1:Fc fusion protein
crimsoncanary wrote 1 year ago: Five Prime have initiated a Phase I trial of its FGFR1:Fc fusion protein FP-1039, in patients with a … more →
E Mercks Matuzumab effective in pancreatic cell lines/models
crimsoncanary wrote 1 year ago: E Mercks Matuzumab (EMD72000) reduced ErbB-1 phosphorylation and downstream MAPK and AKT signaling i … more →
AVEO initiate Phase Ib trial with VEGFR inhibitor AV-951
crimsoncanary wrote 1 year ago: AVEO Pharmaceuticals has initiated a Phase Ib clinical study its VEGFR 1/2/3 receptor inhibitor AV- … more →
VEGF-Trap effective in Phase II AMD trial
crimsoncanary wrote 1 year ago: Phase II data released by Bayer and Regeneron show VEGF Trap-Eye is effective in patients with wet a … more →
NICE recommends against Avastin, Nexavar, Sutent and Torisel for Kidney Cancer
crimsoncanary wrote 1 year ago: The UK’s National Institute for Health and Clinical Excellence (NICE) has made a preliminary r … more →
Phase II nimotuzumab data supports continued development
crimsoncanary wrote 1 year ago: YM Biosciences have released Phase II data that show its EFGR antibody nimotuzumab to be effective i … more →
BMS proposes acquisition of ImClone at $60/share
crimsoncanary wrote 1 year ago: Bristol-Myers Squibb (BMS) has proposed to enter into an agreement to acquire ImClone Systems for $6 … more →
AstraZeneca publish series of CSF-1R inhibitors for the treatment of cancer
crimsoncanary wrote 1 year ago: AstraZeneca have published a series of pyridyl and thiazolyl bisamide CSF-1R inhibitors for the trea … more →
Merck Serono receive EU approval for Erbitux in Metastatic Colorectal Cancer
crimsoncanary wrote 1 year ago: Merck Serono have received EU approval for Erbitux in EGFR expressing, KRAS wild-type metastatic col … more →
YM Biosciences EGFR MAb nimotuzumab safe in Phase I
crimsoncanary wrote 1 year ago: Data to be presented at the AACR Centennial Conference on Translational Cancer Medicine today will d … more →
Erbitux approved in Japan for Advanced Colorectal Cancer
crimsoncanary wrote 1 year ago: ImClone Systems have announced that Erbitux (cetuximab) has been approved in Japan for use in treati … more →
Telik publish small molecule insulin receptor ligands
crimsoncanary wrote 1 year ago: Telik have published a novel class of 5-substituted isophthalamide insulin receptor ligands … more →
ImClone initiate Phase II study of IGF-1R MAb for Advanced Soft Tissue Sarcoma
crimsoncanary wrote 1 year ago: ImClone Systems have announced the start of a Phase II clinical trial of IMC-A12, its IGF-1R monoclo … more →
Coadministration of CDK inhibitor seliciclib with EGFR inhibitors increases activity
crimsoncanary wrote 1 year ago: Studies published by Cyclacel on the coadministration of CDK inhibitor seliciclib with EGFR/HER2 inh … more →
Takeda submit Japanese NDA for panitumumab in progressed and/or relapse colorectal cancer
crimsoncanary wrote 1 year ago: Takeda have submitted a New Drug Application to the Ministry of Health Labour and Welfare in Japan f … more →
Preemptive Treatment May Significantly Reduce Skin Toxicities in Patients Receiving Panitumumab
crimsoncanary wrote 1 year ago: Data presented today at the 10th World Congress on Gastrointestinal Cancer shows that preemptive tre … more →
Axelar initiate Phase I/II trial with IGF-1R drug AXL1717
crimsoncanary wrote 1 year ago: Axelar has initiated a Phase I/II clinical trial in cancer patients with its insulin-like growth fac … more →
Axelar commence Phase I/II trial of IGF-1R inhibitor AXL-1717
crimsoncanary wrote 1 year ago: Axelar have initiated a phase I/II clinical trial of its IGF-1R inhibitor AXL1717 in cancer patients … more →
